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OBJECTIVES: To evaluate transrectal ultrasound, amplitude Doppler ultrasound, conventional T2-weighted
magnetic resonance imaging, spectroscopy and dynamic contrast-enhanced magnetic resonance imaging in
localizing and locally staging low-risk prostate cancer.
INTRODUCTION: Prostate cancer has been diagnosed at earlier stages and the most accepted classification for low-
risk prostate cancer is based on clinical stage T1c or T2a, Gleason score #6, and prostate-specific antigen (PSA)
#10 ng/ml.
METHODS: From 2005 to 2006, magnetic resonance imaging was performed in 42 patients, and transrectal
ultrasound in 26 of these patients. Seven patients were excluded from the study. Mean patient age was 64.94 years
and mean serum PSA was 6.05 ng/ml. The examinations were analyzed for tumor identification and location in
prostate sextants, detection of extracapsular extension, and seminal vesicle invasion, using surgical pathology
findings as the gold standard.
RESULTS: Sixteen patients (45.7%) had pathologically proven organ-confined disease, 11 (31.4%) had positive
surgical margin, 8 (28.9%) had extracapsular extension, and 3 (8.6%) presented with extracapsular extension and
seminal vesicle invasion. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and
accuracy values for localizing low-risk prostate cancer were 53.1%, 48.3%, 63.4%, 37.8% and 51.3% for transrectal
ultrasound; 70.4%, 36.2%, 65.1%, 42.0% and 57.7% for amplitude Doppler ultrasound; 71.5%, 58.9%, 76.6%,
52.4% and 67.1% for magnetic resonance imaging; 70.4%, 58.7%, 78.4%, 48.2% and 66.7% for magnetic resonance
spectroscopy; 67.2%, 65.7%, 79.3%, 50.6% and 66.7% for dynamic contrast-enhanced magnetic resonance imaging,
respectively. Sensitivity, specificity, PPV, NPV and accuracy values for detecting extracapsular extension were
33.3%, 92%, 14.3%, 97.2% and 89.7% for transrectal ultrasound and 50.0%, 77.6%, 13.7%, 95.6% and 75.7% for
magnetic resonance imaging, respectively. For detecting seminal vesicle invasion, these values were 66.7%, 85.7%,
22.2%, 97.7% and 84.6% for transrectal ultrasound and 40.0%, 83.1%, 15.4%, 94.7% and 80.0% for magnetic
resonance imaging.
CONCLUSION: Although preliminary, our results suggest that imaging modalities have limited usefulness in
localizing and locally staging clinically low-risk prostate cancer.
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INTRODUCTION
The widespread use of prostate-specific antigen (PSA)
testing, associated with both improved biopsy techniques
for diagnosis and public awareness has led to an increase in
prostate cancer detection in recent decades.1 Moreover, this
phenomenon has been accompanied by a decrease in the
mortality rate related to prostate cancer in many countries,
probably because it is being detected at earlier stages, when
tumors are often small and of low aggressiveness.2
One of the most important current challenges in prostate
cancer is to distinguish patients with clinically relevant
disease, who may benefit from early radical treatment, from
those with more indolent disease, avoiding overtreatment
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and consequent morbidity. The classification of prostate
cancer into high-, intermediate-, and low-risk disease is an
attempt to stratify patients’ management focusing on their
individual needs.3
A recent published study has clearly demonstrated this
downward stage migration, analyzing data from over 8000
men diagnosed with prostate cancer. In the last two
decades, the rate of detection of low-risk prostate cancer
has shown an increase, ranging from 28% to 45.3%.4
One of the most accepted classifications for low-risk
prostate cancer was proposed by D’Amico et al.5 more than
10 years ago, and is based on prognostic factors that reduce
the probability of post-therapy PSA failure (,25% at
5 years). Low-risk prostate cancer was defined as clinical
T-stage T1c or T2a (undetected or limited to one lobe on
digital rectal examination), Gleason score #6, and PSA
#10 ng/ml.
Nevertheless, this definition of low-risk cancer is based on
pretreatment clinical assessment and can represent a
significant or insignificant tumor on surgical pathology,
with widely different prognosis. The pathological definition
of insignificant tumor consists in an organ-confined cancer
with a total volume #0.5 ml, and no poorly differentiated
components (Gleason $4) on surgical histopathology.6
There is still no reliable non-invasive marker to predict
individual profiles in the low-risk category of prostate
cancer. Imaging is gaining widespread acceptance, espe-
cially magnetic resonance imaging (MRI), which provides
an excellent zonal anatomy resolution, besides functional
and metabolic information. Although the importance of
these methods for tumor diagnosis and location, assessment
of tumor aggressiveness, treatment planning, and follow-up
have been well studied, the potential of imaging in the
evaluation of low-risk prostate cancer still needs further
investigation.7
The aim of this study was to evaluate transrectal
ultrasound (TRUS), amplitude Doppler ultrasound
(ADUS), conventional MRI, magnetic resonance spectro-
scopy (MRS) and dynamic contrast-enhanced imaging
(DCE-MRI) in localizing and locally staging low-risk
prostate cancer, using surgical pathology findings as gold
standard.
MATERIALS AND METHODS
Patient characteristics and demographics
Institutional Review Board approval and written infor-
med consent from all patients were obtained for this pros-
pective study. Patient data were collected from January 2005
to December 2006. Forty-two patients referred from the
Urology Department met the following inclusion criteria: a)
ultrasound-guided biopsy-proven prostate cancer, b) no
prior history of hormonal blockade, c) candidate for retro-
pubic prostatectomy, d) clinical T-stage T1c–T2a, e) biopsy
Gleason score #6 and f) PSA #10 ng/ml. MRI examination
was performed with a minimal interval of 21 days after
prostate biopsy to minimize hemorrhagic artifacts. Serum
level of PSA, Gleason grade at biopsy, and digital rectal
examination results were collected from the medical
records.
Of these 42 patients, 3 were excluded from the study
because prostatectomy had been performed at other
institutions, 3 were referred to other therapy due to high
surgical risk and 1 died from non-related causes before
surgery.
The final group consisted of 35 patients who underwent
MRI examination before surgery, 26 of whom were also
submitted to TRUS. The other nine patients declined to
undergo ultrasound after their initial enrollment.
The mean patient age was 64.94 years (range 50–77 years),
mean serum level of PSA was 6.05 ng/ml (range 2.6–
10.0 ng/ml). Two patients (5.7%) had a total Gleason biopsy
score of 5, and the remaining 33 (94.3%) had a total Gleason
biopsy score of 6. The mean intervals between imaging
examinations and surgery were 49.34 days for MRI and
48.35 for TRUS (range 4–145 days).
Conventional MRI technique
Endorectal MRI was performed with a 1.5-T MRI system
(Signa; GE Medical Systems, Milwaukee, WI, USA), using a
pelvic phased-array coil (Torso PA; GE Medical Systems) in
combination with a commercially available balloon-covered
expandable endorectal coil (Endo ATD; Medrad, Pittsburgh,
PA, USA) for signal reception. The endorectal coil was
inflated with 60 ml of liquid perfluorocarbon to reduce the
high magnetic field susceptibility at the air–tissue interface
and improve the quality of MR spectroscopic imaging data.
T1-weighted (T1W) axial fast multiplanar spoiled gradi-
ent-echo (FMSPGR) images from the pelvis were obtained
from the aortic bifurcation to the symphysis pubis with the
following parameters: repetition time (TR)/echo time (TE),
200/4.2; flip angle, 90 ;˚ slice thickness, 7 mm; interslice gap,
1 mm; field of view (FOV), 30 cm; matrix, 256 6 192;
frequency direction, transverse (right to left); and number of
excitations (NEX), 1. Thin-section, high spatial resolution
axial, sagittal and coronal T2-weighted (T2W) fast spin-echo
images from below the prostate apex to above the seminal
vesicles (SSVV) were obtained with the following para-
meters: TR/TE, 4000/150; slice thickness, 3 mm; interslice
gap, 0–1 mm; FOV, 14 cm; matrix, 256 6 192; frequency
direction, anteroposterior (AP) (for sagittal and axial
images), no-phase-wrap (to avoid phase oversampling);
and NEX, 3.
MRI spectroscopic technique
After reviewing the transverse T2W images, a spectro-
scopic imaging volume was selected to maximize coverage
of the whole prostate. Three-dimensional MRS data were
acquired by using point-resolved spatially localized spectro-
scopy (PRESS), which was optimized for quantitative
detection of both choline and citrate. Water and lipid
suppression was achieved by using the spectral-spatial
pulses capable of both volume selection and frequency
selection. Outer voxel saturation pulses were also used to
eliminate signals from adjacent tissues. Data sets were
acquired as 166868 phase-encoded spectral arrays (1024
voxels; nominal spatial resolution, 0.34 cm3; 1000/130;
acquisition time, 17 min).
Dynamic contrast-enhanced MRI technique
High spatial resolution DCE-MRI was performed with
application of a fast three-dimensional T1W spoiled
gradient-echo sequence with a voxel size of 1.79 mm3
(0.9560.6363 mm), as described in a recent study.8 Seven
three-dimensional data sets, two before and five after
contrast agent administration, were acquired under a 1 min
and 35 s temporal resolution and a total duration of 11 min
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and 8 s. The MR contrast agent, gadopentetate dimeglumine
(Magnevist, Schering), was injected as a bolus at a dose of
0.1 mmol per kilogram of body weight at 2 ml/s starting
5–7 s before the end of the second acquisition, followed by a
20-ml saline flush.
MRI interpretation
All MRI data were analyzed by the same radiologist, with
8 years’ experience in prostate MRI. The reader was not
completely blinded since he was aware that the patient had
biopsy-proven prostate cancer, but unaware of any other
clinical or laboratory data. Tumor identification was defined
by a conspicuous hypointense nodule or an ill-defined low-
signal area on T2W images, with tumor location being
determined within prostate sextants. The diagnostic criteria
used to determine the extracapsular extension (ECE)
included at least one of the following: irregular capsular
bulge, direct extension of low signal intensity tumor into
periprostatic fat and/or obliteration of the rectoprostatic
angle.9 Seminal vesicle invasion (SVI) was defined as loss of
the normal SSVV architecture, focal or diffuse areas of low
signal intensity within the SSVV and/or direct extension of
the low signal intensity of tumor from the base of the
prostate to the SSVV.10
MRS data were digitally processed by using Functool
software (Advantage workstation, GE Healthcare), overlaid
on the corresponding transverse T2W images. Signal-to-
noise ratios were automatically calculated as the ratio
between citrate or choline peak amplitude and the standard
deviation of the noise over the 0.53–0.96 ppm range. Voxels
considered suitable had signal-to-noise ratio $2 (ranging
from 2 to 8). Ten patients were excluded from spectral
analysis because they presented voxels of insufficient
spectral quality, signal-to-noise ,2 or were spectroscopi-
cally contaminated because of insufficient water or fat
suppression. Suitable spectroscopic voxels were analyzed
by a quantitative and qualitative approach: positivity was
determined by a choline plus creatine-to-citrate ratio $0.7
and by an elevation of the choline and reduction of
the citrate peaks, such that these peaks were of similar
height or the choline one was higher.11 One positive voxel
defined tumor presence within its sextant, independently of
coexisting abnormal T2W findings.
DCE-MRI was processed using the three-timepoint model
to analyze the time evolution of contrast enhancement.8 A
positive pattern was defined as increased wash-in followed
by a decreasing curve characterizing washout, and at least
one positive ROI within the sextant was sufficient to define
its positivity. Dynamic analysis was performed indepen-
dently of the T2W images. Steady state and continuous
enhancement patterns were considered negative for cancer.
Post-biopsy hemorrhage signs within the prostate on T1W
images were identified in three patients without significant
implications for MRI analysis.
Transrectal ultrasound technique and
interpretation
All the TRUS examinations were performed and inter-
preted by the same radiologist, with 15 years’ experience in
prostate ultrasound, who was blinded to all patient
information except for biopsy-proven prostate cancer. All
the examinations were performed in a General Electric
Logiq 9 equipment (GE Medical Systems) with a probe
frequency of 7.5 MHz. TRUS gray-scale findings for tumor
identification were defined as the presence of a definite
hypoechoic nodule or an area of heterogeneous echotexture;
tumor location was determined within the prostate sextants.
The assessment of the ECE depended on identification of an
irregular bulge in the prostate contour, direct extension of
solid tissue in the periprostatic fat and/or rectoprostatic
angle obliteration. SVI was characterized by thickening and
hypoechogenicity of the SSVV. ADUS was then performed
independently of gray-scale findings. Doppler gain was set
as high as possible without background noise. The amount
of flow within each sextant was determined on the basis of
visual inspection of the pixel density, and hypervascularity
was defined as the presence of higher than normal blood
flow in each distinct sextant of the prostate, with irregular,
tortuous, and/or disorganized vessels, as well as areas of
vascular asymmetry being interpreted as suspicious for
cancer.
Histopathological results
After preparation, axial step sections were obtained at 3-
to 4-mm intervals, in planes closely paralleling the MR
images, and stained with hematoxylin and eosin (HE).
Tumor presence and Gleason grade were recorded for each
sextant, as well as the presence of ECE and surgical positive
margins. SVI was recorded by side of involvement. The final
classification was performed using TNM staging classifica-
tion and the Gleason score and used as the reference
standard.
Statistical analysis
The sensitivity, specificity, accuracy, PPVs and NPVs
were calculated for tumor identification in the different
techniques evaluated: TRUS, ADUS, MRI, MRS and DCE-
MRI. Sensitivity, specificity, accuracy, PPVs and NPVs were
also calculated for ECE and SVI detection by TRUS and
MRI. The kappa index of agreement was calculated for each
technique. All these analyses utilized histopathological
results as the gold standard, according to sextant localiza-
tion.
RESULTS
From the 35 patients with clinically defined low-risk
prostate cancer who underwent radical prostatectomy, only
16 (45.7%) had pathologically proven organ-confined dis-
ease; clinical and histopathological variables are demon-
strated in Tables 1 and 2, respectively. Both clinical stage
and biopsy Gleason grade underestimated the surgical
findings. Positive surgical margins were found in 11
patients (31.4%), ECE was detected in eight patients
(28.9%); three of them (8.6%) also presented with SVI.
The performance of the different imaging methods
evaluated in localizing low-risk prostate cancer is demon-
strated in Table 3. Although TRUS presented slight
Table 1 - Distribution of preoperative clinical variables.
PSA level (ng/ml) (mean ¡ SD) 6.05 ¡ 2.16
Biopsy Gleason grade
5 2 (5.7%)
6 33 (94.3%)
Clinical stage
T1c 29 (82.9%)
T2a 6 (17.1%)
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agreement with the histopathology based on the kappa
index, the use of ADUS increases the sensitivity (from 53.1%
to 70.4%; p 0.0187), with a discrete decrease in specificity
(from 48.3% to 36.2%). MRI presented reasonable kappa
index agreement, and the inclusion of MRS or DCE-MRI did
not produce a significant improvement in the performance
when compared with MRI sequence analysis (sensitivity
values of 71.5% for MRI, 70.4% for MRS and 67.2% for DCE-
MRI, p.0.05).
TRUS and MRI were also evaluated for detecting ECE,
both demonstrating similar accuracies compared with the
surgical pathology (kappa 0.15 and 0.12, respectively). The
sensitivity, specificity, PPV, NPV and accuracy for detecting
ECE were 33.3%, 92.0%, 14.3%, 97.2% and 89.7% for TRUS,
and 50.0%, 77.6%, 13.7%, 95.6% and 75.7% for MRI,
respectively (Table 4).
In the group under evaluation, only three patients (8.6%)
presented with SVI, being unilateral in one patient and
bilateral in the other two (Table 5). Although both methods
showed high specificity, NPV, and accuracy (85.7%, 97.7%
and 84.6% for TRUS and 83.1%, 94.7% and 80.0% for MRI),
they lacked sensitivity and PPV.
DISCUSSION
There has been an increasing incidence of clinically
defined low-risk prostate cancers in PSA-screened popula-
tions, for whom disease management remains controversial.
There is no reliable method to distinguish patients who
have indolent disease from those with progressive and life-
threatening tumors within this low-risk group.12
Adverse pathologic features at surgery are defined as any
of these criteria: tumor volume $0.5 ml, extraprostatic
extension (EPE), positive surgical margins, or the presence
of Gleason score .6,1. Based on this definition, all of our 35
patients with clinically defined low-risk prostate cancer had
adverse pathologic findings: all of them presented tumor
volume $0.5 ml, 8 patients had EPE (all of them with ECE
and 3 also with SVI), 22 presented a Gleason score .6 and
11 had positive surgical margins. A recent meta-analysis
reviewed 29 articles (1995–2006) that retrospectively exam-
ined outcomes in men with microfocal prostate cancer on
biopsy, almost all of whom had low-risk disease according
to the D’Amico classification, and up to 84% of them had
adverse pathological findings at radical prostatectomy.12
However, not all patients with adverse pathologic results
have clinically significant disease.
The ability to determine the correct cancer location within
the prostate and the number of sextants involved has
important clinical value, because tumor volume is a relevant
prognostic factor and also for considering the actual role of
the local therapies. Huge heterogeneity exists in the
available MRI literature, strongly affected by methodologi-
cal and population variables, with cancer detection sensi-
tivity varying between 37% and 90%.13 Although large-
volume cancers can be reasonably well detected by imaging,
small lesions have been difficult to identify or measure
accurately.3 Also, aggressive tumors with higher Gleason
scores present more evident architectural disarray on
histology, probably improving their differentiation from
the normal gland in imaging studies. In contrast, our
difficulty in identifying many lesions in this study may be
explained by the lower Gleason grades, represented by
more differentiated cells that may be indistinguishable from
the normal gland on imaging (Figures 1 and 2).
The results of several studies have suggested that MRS
may provide additional useful information based on the
metabolic changes associated with the disease, which might
even precede morphological changes, improving assess-
ment of tumor location, volume, staging, and estimation of
aggressiveness.14 However, a recently published prospec-
tive multicenter study that evaluated 110 patients with MRI
and MRS demonstrated that the accuracy of combined MRI–
MRS for sextant localization of prostate cancer in the
peripheral zone is equal to that obtained by MRI alone.15
Table 2 - Distribution of histopathological variables
(post-prostatectomy specimen).
Gleason grade
6 (3 + 3) 13 (37.1%)
7 (3 + 4) 18 (51.4%)*
7 (4 + 3) 03 (8.6%){
8 (3 + 5) 01 (2.9%)
Histopathological stage
pT2a 02 (5.7%)
pT2b 03 (8.6%)
pT2c 11 (31.4%)
pT2+ (positive surgical margins) 11 (31.4%)
pT3a (extracapsular extension) 08 (22.9%)
pT3b (seminal vesicle invasion) 03 (8.6%)
*4 of which had tertiary Gleason 5.
{1 of which had tertiary Gleason 5.
Table 3 - Evaluation of different imaging methods in localizing low-risk prostate cancer.
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) kappa
TRUS 53.1 48.3 63.4 37.8 51.3 0.01
ADUS 70.4 36.2 65.1 42.0 57.7 0.07
MRI 71.5 58.9 76.6 52.4 67.1 0.30
MRS 70.4 58.7 78.4 48.2 66.7 0.28
DCE-MRI 67.2 65.7 79.3 50.6 66.7 0.31
Table 4 - Evaluation of TRUS and MRI in detecting ECE of
low-risk prostate cancer.
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%) kappa
TRUS 33.3 92.0 14.3 97.2 89.7 0.15
MRI 50.0 77.6 13.7 95.6 75.7 0.12
Table 5 - Evaluation of TRUS and MRI in detecting SVI of
low-risk prostate cancer.
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%) kappa
TRUS 66.7 85.7 22.2 97.7 84.6 0.27
MRI 40.0 83.1 15.4 94.7 80.0 0.13
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Figure 1 - 64-year-old man with prostate cancer (prostate specific antigen (PSA) level 5.2 ng/ml). (a) Transverse transrectal ultrasound
(TRUS) demonstrates a hypoechoic nodule in the right mid-gland peripheral zone, hypervascularized in amplitude Doppler ultrasound
(ADUS) (b). Transverse T2-weighted (T2W) magnetic resonance imaging (MRI) (c) shows a hypointense nodule in the right mid-gland.
This voxel (d) and the corresponding amplitude times frequency spectroscopic graphic (e) shows reduced citrate and increased choline–
creatine levels, suspicious for prostate cancer. Transverse T1W DCE-MRI (f) demonstrates increased vascularization in the nodule (pink
region of interest (ROI)) and normal hypovascularized peripheral zone in the left mid-gland (green ROI), characterized on graphic (g)
by washin followed by a decreasing washout curve and continuous enhancement patterns, respectively. Surgically confirmed
adenocarcinoma Gleason score 7 (4 + 3) in the right mid-gland – HE 4006 (h).
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Figure 2 - 68-year-old man with prostate cancer (prostate-specific antigen (PSA) level 2.6 ng/ml). (a) Transverse transrectal ultrasound
(TRUS) and amplitude Doppler ultrasound (ADUS) (b) do not demonstrate any suspect finding in the peripheral zone. Transverse T2W
MRI (c) shows normal high-signal intensity in the peripheral zone, except for discrete ill-defined areas of hypointensity. Four
contiguous voxels in the left prostate mid-gland/apex (d) and the corresponding amplitude times frequency spectroscopic graphic (e)
shows normal metabolites concentrations, with low choline and increased citrate levels. Transverse T1W DCE-MRI (f) demonstrates
normal hypovascularized peripheral zone in both sides (pink and green ROIs), characterized on graphic (g) by steady state
enhancement pattern. Surgically confirmed adenocarcinoma Gleason score 6 (3 + 3) in the in the left base, mid-gland and apex – HE
4006 (h).
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Although not directly focused on the low-risk group, the
mean PSA level of 5.9 ng/dl found in that study may be
because that population was skewed toward low-risk and
low-volume cancers. Another study evaluated the accuracy
of MRI in predicting organ-confined prostate cancer with
and without MRS, and found that although the radiologists’
performance was slightly higher with combined MRS this
difference was not considered statistically significant.16
Similarly, the addition of MRS did not improve the ability
to localize cancers in our study.
Few studies have been performed for evaluating the role
of MRI contrast agents in prostate cancer detection. A recent
one showed that DCE-MRI was more sensitive than MRI for
tumor localization (50% 6 21%) without lacking specificity
(85% 6 81%).17 In our study, MRI and DCE-MRI showed
similar sensitivities (71.5% and 67.2%, respectively), and
DCE-MRI allowed an increment in specificity from 58.9% to
65.7%. Once again, the low-volume, low-aggressive tumors
in our study group might have impaired the imaging
results.
A large literature variation also exists in the local staging
performance of prostate MRI, as demonstrated by a large
meta-analysis, in part due to the lack of definitive criteria
standardization for ECE and to the variability among the
studied populations.18 Different studies in which MRI was
used for prostate cancer staging and/or prediction of ECE
have yielded a range of values for sensitivity (51–89%),
specificity (68–87%) and accuracy (56–88%).8 One study that
evaluated MRI for ECE based on positivity criteria similar to
ours obtained sensitivity, specificity, PPV, and NPV of
42.2%, 95.4%, 74.5%, and 83.8%, respectively.19 However,
that study included patients with presurgical Gleason scores
ranging from 5 to 10. Although our study presented higher
sensitivity and NPV (50% and 95.6%, respectively), we had
significantly lower specificity and PPV, which may be
explained by the differences in the selected patient group
(presurgical Gleason score #6).
We included TRUS and ADUS in this evaluation because
of their higher availability in many centers, associated with
lower costs than MRI. TRUS is considered to have poor
accuracy for prostate cancer identification and staging in the
literature, even with ADUS technical improvements.20 In
spite of that, TRUS and particularly ADUS presented results
similar to those of MRI in the present study. Such results
may be attributed to specific imaging characteristics of
this low-risk cancer population, in which MRI has poor
accuracy.
Our study has some limitations. First, we do not have
data about the number of biopsy cores or its positive
percentual score, as we only had access to the biopsy
Gleason score in the patients’ medical records. Although
our Gleason biopsy understaging rate of 62.9% was slightly
high, it does not differ substantially from the available
literature. Some studies compared the correlation between
Gleason scores of needle biopsies and radical prostatectomy
specimens, with biopsy Gleason understaging varying from
38% to 71.7%.21–25 This relatively low level of agreement
was predominantly due to the undergrading of low-grade
carcinoma in needle biopsies, although the agreement was
more exact in high-grade carcinoma, as described by Lotan
and Epstein.26
Also, we included a relatively small number of patients
and, as expected for a clinically defined low-risk group, our
positive histology rate for EPE was small, with considerable
impact on our final statistical results. Moreover, only three
patients presented with SVI, with a consequent overestima-
tion of the false-negative results and an important repercus-
sion in the sensitivity value. Additionally, as only one
reader evaluated each method (TRUS and MRI), we could
not assess interobserver variability.
CONCLUSION
Our preliminary results suggest that MRI using different
functional sequences and techniques, TRUS and ADUS have
limited usefulness in evaluating low-risk prostate cancer.
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